VERAXA Secures Financing to Advance Cancer Therapies Pipeline
- Financing Enhances Flexibility: VERAXA has signed a securities purchase agreement with an institutional investor to issue a senior secured note of $27.5 million, strengthening its financial position to support the business combination with Voyager, which is expected to advance its cancer therapy pipeline into clinical development.
- Equity Financing Agreement: VERAXA has entered into a $50 million share purchase agreement with Lincoln Park Capital Fund, allowing it to sell common stock at market prices over a 24-month period, ensuring flexibility and control in future financing endeavors.
- Listing Plans Progress: VERAXA has applied for listing on the Nasdaq Capital Market, with shares expected to trade under the symbol “VRXA” post-merger, marking a significant step towards public market entry and enhancing its visibility and investor confidence.
- Strategic Development Goals: This financing not only enables VERAXA to advance its BiTAC-TCE and BiTAC-ADC programs into clinical development but also solidifies its market position in the competitive biotech sector, attracting increased investor interest.
Trade with 70% Backtested Accuracy
Analyst Views on VACH
About VACH
About the author
VERAXA Secures Financing to Advance Cancer Therapies Pipeline
- Financing Enhances Flexibility: VERAXA has signed a securities purchase agreement with an institutional investor to issue a senior secured note of $27.5 million, strengthening its financial position to support the business combination with Voyager, which is expected to advance its cancer therapy pipeline into clinical development.
- Equity Financing Agreement: VERAXA has entered into a $50 million share purchase agreement with Lincoln Park Capital Fund, allowing it to sell common stock at market prices over a 24-month period, ensuring flexibility and control in future financing endeavors.
- Listing Plans Progress: VERAXA has applied for listing on the Nasdaq Capital Market, with shares expected to trade under the symbol “VRXA” post-merger, marking a significant step towards public market entry and enhancing its visibility and investor confidence.
- Strategic Development Goals: This financing not only enables VERAXA to advance its BiTAC-TCE and BiTAC-ADC programs into clinical development but also solidifies its market position in the competitive biotech sector, attracting increased investor interest.
Voyager Acquisition's Merger with Veraxa Biotech Approved
- Merger Approval: Voyager Acquisition (VACHU) received approval for its merger with Veraxa Biotech AG on March 12, with the combined entity expected to trade on Nasdaq under the symbol VRXA, marking a significant step in the company's strategic expansion.
- Share Redemption Status: Approximately 99.67% of Class A shares (25.2 million shares) were submitted for redemption and not withdrawn, indicating strong investor interest and participation in the merger, which enhances the capital base of the post-merger company.
- Trust Account Balance: Following the redemption of 25.2 million shares, about $0.89 million will remain in the trust account, providing liquidity support for the merged entity and ensuring operational stability and growth potential.
- Transaction Conditions: The closing of this transaction is contingent upon Nasdaq approval and other customary closing conditions, highlighting the company's focus on compliance and market adaptability to ensure a smooth merger process.
VOYAGER ACQUISITION CORPORATION RECEIVES GREEN LIGHT FOR BUSINESS MERGER WITH VERAXA BIOTECH AG
Business Combination Announcement: Voyager Acquisition Corporation has announced the approval of its business combination with Verax BioTech.
Strategic Partnership: This merger aims to enhance Voyager's capabilities and expand its market presence in the biotechnology sector.
VERAXA Biotech Merger with Voyager Approved by Shareholders
- Merger Approval: VERAXA Biotech received shareholder approval for its merger with Veraxa Biotech Holding AG and the issuance of new shares at the Extraordinary General Meeting on February 27, 2026, marking a significant step towards its business combination with Voyager Acquisition Corp.
- Capital Increase: The EGM also approved an ordinary capital increase of up to CHF 223,400, which is expected to provide necessary funding for the combined company, thereby enhancing its competitive position in the cancer therapy market.
- Stable Management Team: Post-merger, VERAXA will continue to be led by CEO Christoph Antz, ensuring operational continuity and strategic direction during the integration process, further solidifying its innovative position in antibody-drug conjugates and bispecific T cell engagers.
- Future Outlook: Upon completion of the merger, the new company is expected to trade on NASDAQ under the symbol “VRXA,” allowing VERAXA to expand its influence in the cancer treatment market and meet the growing demand for safer and more effective cancer therapies.
Shareholder Notice: M&A Class Action Firm Ongoing Investigation into the Merger Involving PBBK, VACH, LCTC, and SMLR
Class Action Firm Recognition: Monteverde & Associates PC, led by attorney Juan Monteverde, is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders.
PB Bankshares Investigation: The firm is investigating PB Bankshares Inc. regarding its sale to Norwood Financial Corp., where shareholders can choose between shares or cash, with a shareholder vote scheduled for December 10, 2025.
Other Mergers and Acquisitions: The firm is also involved in cases related to Voyager Acquisition Corp.'s merger with Veraxa Biotech AG, Lifeloc Technologies' merger with Electronic Systems Technology, and Semler Scientific's sale to Strive, Inc.
Contact Information: Shareholders with concerns or seeking more information can contact Juan Monteverde via email or phone, with services offered at no cost or obligation.
VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC
Business Combination Announcement: VERAXA Biotech AG and Voyager Acquisition Corp. have filed a registration statement with the SEC regarding their proposed business combination, which is expected to close in Q4 2025, valuing VERAXA at approximately $1.64 billion.
Transaction Details: The merger will result in existing VERAXA shareholders receiving shares in the combined company without cash proceeds, while VERAXA anticipates access to around $253 million in cash held by Voyager, subject to shareholder approvals and customary closing conditions.
VERAXA Secures Financing to Advance Cancer Therapies Pipeline
- Financing Enhances Flexibility: VERAXA has signed a securities purchase agreement with an institutional investor to issue a senior secured note of $27.5 million, strengthening its financial position to support the business combination with Voyager, which is expected to advance its cancer therapy pipeline into clinical development.
- Equity Financing Agreement: VERAXA has entered into a $50 million share purchase agreement with Lincoln Park Capital Fund, allowing it to sell common stock at market prices over a 24-month period, ensuring flexibility and control in future financing endeavors.
- Listing Plans Progress: VERAXA has applied for listing on the Nasdaq Capital Market, with shares expected to trade under the symbol “VRXA” post-merger, marking a significant step towards public market entry and enhancing its visibility and investor confidence.
- Strategic Development Goals: This financing not only enables VERAXA to advance its BiTAC-TCE and BiTAC-ADC programs into clinical development but also solidifies its market position in the competitive biotech sector, attracting increased investor interest.
Voyager Acquisition's Merger with Veraxa Biotech Approved
- Merger Approval: Voyager Acquisition (VACHU) received approval for its merger with Veraxa Biotech AG on March 12, with the combined entity expected to trade on Nasdaq under the symbol VRXA, marking a significant step in the company's strategic expansion.
- Share Redemption Status: Approximately 99.67% of Class A shares (25.2 million shares) were submitted for redemption and not withdrawn, indicating strong investor interest and participation in the merger, which enhances the capital base of the post-merger company.
- Trust Account Balance: Following the redemption of 25.2 million shares, about $0.89 million will remain in the trust account, providing liquidity support for the merged entity and ensuring operational stability and growth potential.
- Transaction Conditions: The closing of this transaction is contingent upon Nasdaq approval and other customary closing conditions, highlighting the company's focus on compliance and market adaptability to ensure a smooth merger process.
VOYAGER ACQUISITION CORPORATION RECEIVES GREEN LIGHT FOR BUSINESS MERGER WITH VERAXA BIOTECH AG
Business Combination Announcement: Voyager Acquisition Corporation has announced the approval of its business combination with Verax BioTech.
Strategic Partnership: This merger aims to enhance Voyager's capabilities and expand its market presence in the biotechnology sector.
VERAXA Biotech Merger with Voyager Approved by Shareholders
- Merger Approval: VERAXA Biotech received shareholder approval for its merger with Veraxa Biotech Holding AG and the issuance of new shares at the Extraordinary General Meeting on February 27, 2026, marking a significant step towards its business combination with Voyager Acquisition Corp.
- Capital Increase: The EGM also approved an ordinary capital increase of up to CHF 223,400, which is expected to provide necessary funding for the combined company, thereby enhancing its competitive position in the cancer therapy market.
- Stable Management Team: Post-merger, VERAXA will continue to be led by CEO Christoph Antz, ensuring operational continuity and strategic direction during the integration process, further solidifying its innovative position in antibody-drug conjugates and bispecific T cell engagers.
- Future Outlook: Upon completion of the merger, the new company is expected to trade on NASDAQ under the symbol “VRXA,” allowing VERAXA to expand its influence in the cancer treatment market and meet the growing demand for safer and more effective cancer therapies.
Shareholder Notice: M&A Class Action Firm Ongoing Investigation into the Merger Involving PBBK, VACH, LCTC, and SMLR
Class Action Firm Recognition: Monteverde & Associates PC, led by attorney Juan Monteverde, is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders.
PB Bankshares Investigation: The firm is investigating PB Bankshares Inc. regarding its sale to Norwood Financial Corp., where shareholders can choose between shares or cash, with a shareholder vote scheduled for December 10, 2025.
Other Mergers and Acquisitions: The firm is also involved in cases related to Voyager Acquisition Corp.'s merger with Veraxa Biotech AG, Lifeloc Technologies' merger with Electronic Systems Technology, and Semler Scientific's sale to Strive, Inc.
Contact Information: Shareholders with concerns or seeking more information can contact Juan Monteverde via email or phone, with services offered at no cost or obligation.
VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC
Business Combination Announcement: VERAXA Biotech AG and Voyager Acquisition Corp. have filed a registration statement with the SEC regarding their proposed business combination, which is expected to close in Q4 2025, valuing VERAXA at approximately $1.64 billion.
Transaction Details: The merger will result in existing VERAXA shareholders receiving shares in the combined company without cash proceeds, while VERAXA anticipates access to around $253 million in cash held by Voyager, subject to shareholder approvals and customary closing conditions.
